Oxford Investment Opportunity Network

The following six companies are seeking investment via the Network as a result of the 21 March OION investment meeting at the Said Business School, Oxford. The descriptions available summarise the investment proposal made by the company. The information is provided by the company and has not been vetted in any way by OION.

If you are interested in receiving further information on any of the companies then please contact us.

Company A has developed MyFeedMe to meet an organisations need for high quality, timely and salient business insight, ensuring the user is placed at the crossroads of a unique and valuable daily flow of information, and maintaining their awareness of critical business current affairs within the context of their day to day needs.
Currently boasting Eon, LEX, Vertex, HBoS, Texas Instruments (US) and Countrywide Home Loans (US) as users, MyFeedMe is the only IP protected application of its type capable of capturing, filtering and analysing Global media, Internet and online data to create unique, user defined content.
We are expecting to raise £600,000 to invest in aggressively taking MyFeedMe to market, maintain our momentum in research and development, recruit key staff to deliver our plans and generate third year revenues of £15m.

Company B is a specialty engineering company focussed on the research and development of medical devices. The company’s key area of expertise is in intravenous (IV) infusion pumps, syringe pumps and related devices.
The medical infusion pump market is worth about $3b per annum and is divided into a number of segments, for example, by site of use - hospital/bedside, home/ambulatory; or type of pump - volumetric/peristaltic, elastomeric, syringe. For each segment user needs vary with emphasis on appropriate “cost per use” and “fitness for purpose”.
Company B’s business model is to conceive, research, design and build its products to prototype stage and then partner with an established IV pump supplier. Company B is currently developing three different devices aimed at different market segments:-
• A simplified ambulatory syringe pump designed for use outside the hospital, compact and lightweight, water proof, with a novel mechanism of action allowing low power consumption.
• An ambulatory infusion pump with a novel pump mechanism allowing the lowest IV “cost per use” available in the market.
• A very low cost drop counter/infusion controller designed for the developing world.

Company C has developed innovative technology for reducing leakage in water distribution systems. Water scarcity is afflicting a growing proportion of the world. The UN predicts that by 2025, two-thirds of the world’s population will have inadequate water supply.

These shortages are driven by a range of factors, including climate change, rising populations, urbanisation and industrialisation. The shortages are exacerbated by poor management of resources and high levels of waste, particularly leakage.

We believe that the most cost effective and quickest way to reduce leakage is through better management of the pressure in the network. If the average pressure in the network can be safely reduced, the leakage level will also be reduced. Less obviously, there is also a big impact on the level of new bursts.

The pressure required in a network varies with the level of demand. We have developed an innovative control system which continually adjusts the pressure in response to demand while making sure that it is never higher than it needs to be. This is based on several new pieces of technology for which we have applied for patents. A prototype system has been successfully tested and we are expecting our first sales in early 2008.

Company D is a biopharmaceutical company built on 15 years of world leading research now developing therapeutic vaccines to treat allergy and autoimmune diseases. With an exciting, innovative product portfolio with impressive commercial and technical achievements, Company D is ideally positioned to capitalise on increasing shareholder demands for large pharmaceutical companies to acquire products or companies.
This is an exciting investment opportunity in a rapidly growing company with:
Experienced management with successful track-record; Pipeline in billion dollar markets built on cutting-edge research:

Patented, market-disruptive platform technology to identify additional peptide-based vaccines and diagnostics; Commercial agreements with two global pharmaceutical companies; Potential for early exit through M&A;.
With the £0.5-1 million financing Company D will complete:
Phase Ib/IIa clinical trial of lead product, ATX-MS-1467; MS diagnostic development; Anti Factor VIII inhibitor product candidate selection; Type 1 diabetes and allergy product candidate identification; Platform technology marketing to partners building on success of Factor VIII programme.

Company E are a software technology provider who enable operators to deliver a best-in-class mobile casino service. We are positioned to take a substantial portion of the mobile phone casino market by providing the capability to service operators and take a share of the revenues – predicted to be $4.6bn by 2009. We already have customers and revenues with a strong pipeline for more. The proprietary platform is built to blue-chip banking and insurance standards and is wholly owned by the company with significant technical advantages over competitors. The company has beaten much larger competitors when put through extensive technical due-diligence and has already received approaches for mergers.
The technology meets stringent Gamcare social responsibility accreditation criteria. We have been granted 5-year remote gaming platform license from Malta, EU. The Directors each have 16 years experience in international technology business. The money is needed to scale by allowing the company to sell to and support more customers. We have a commitment for 40% of the funding required by an OION member.